Bayer's Split-Screen Strategy: Crop Science Carries the Quarter While Pharma Pipeline Delivers in Asia
Published on 08/30/2026 at 16:02 | Editorial boerse-global.de
Bayer's latest quarterly scorecard tells a tale of two very different businesses moving in opposite directions — and the market is rewarding the overall trajectory anyway. The German life-science group confirmed its full-year 2026 guidance alongside second-quarter results that showed its agricultural arm doing the heavy lifting while pharmaceuticals lagged.
Group revenue for the April-to-June period came in at €10.872 billion, up 2.2 percent year on year, with adjusted EBITDA advancing 1.9 percent to €2.144 billion. But beneath those headline numbers sits a pronounced divergence: Crop Science sales climbed 3.5 percent to €4.910 billion, and the division's EBITDA surged 30.2 percent to €902 million. Pharma, by contrast, saw flat sales at €4.458 billion and a 3.6 percent EBITDA decline to €1.055 billion.
The oncology drug Nubeqa provided a rare bright spot in the pharma unit, generating €820 million in quarterly sales and partially offsetting the drag from expiring patents on other products. Net income swung back into positive territory at €219 million, reversing a €199 million loss in the same period last year. Adjusted earnings per share, however, slipped 16.7 percent to €0.95, weighed down by the weaker pharma performance.
Regulatory Momentum in Japan
While the current pharma business struggles, the pipeline is generating fresh catalysts. Bayer has filed an application with Japan's PMDA to expand the label for Kerendia (finerenone) to include adults with non-diabetic chronic kidney disease, building on data from the Phase-III FIND-CKD trial. The company had already submitted a similar application to Chinese regulators at the end of July.
Days before the Japanese filing, Bayer secured a marketing approval in Japan for Sevabertinib — marketed there as Hyrnuo — for patients with HER2-mutated non-small cell lung cancer. The back-to-back developments underscore a deliberate pivot toward specialized therapeutic niches as the company works through broader structural changes elsewhere.
Speaking of managing complex regulatory and operational responsibilities — the same discipline applies to workplace safety. Many employers underestimate the gaps in their risk documentation until an incident occurs. A free toolkit with 41 ready-to-use checklists helps you document hazards and protect your team. Download the free Risk Assessment Toolkit
Balance Sheet Progress and Refinancing
Investors have taken note of the improving financial picture. Net financial debt came in lower than initially projected, signaling that the multi-year deleveraging effort is gaining traction. That progress was underscored in mid-July when Bayer placed a $5 billion dollar-denominated bond across maturities ranging from five to 30 years. The offering was multiple times oversubscribed — a signal that fixed-income investors are regaining confidence in the credit after years of glyphosate-related litigation weighing on the rating.
The legal overhang, however, has not disappeared. Despite a favorable US Supreme Court ruling, Bayer maintains provisions of €11.8 billion for the current year, a cautious stance suggesting management sees no quick resolution to the claims wave.
Structural Moves in Agriculture
On the operational front, Bayer transferred its US glyphosate business into a newly created subsidiary, Ruveon (also referenced as Ruvon LLC), based in St. Louis, in early July. The entity now handles pricing, market strategy, production, and logistics for the controversial herbicide in the US — a structure designed to sharpen operational agility while ring-fencing legal and operational risk without a full divestiture.
The agricultural division is also looking further ahead. In July, Bayer struck a licensing partnership with French seed company RAGT aimed at broad commercialization of hybrid wheat — though the payoff is not expected until the early 2030s.
New Leadership, Same Guidance
The quarterly presentation also marked the official debut of Judith Hartmann as chief financial officer, succeeding Wolfgang Nickl. Her first appearance coincided with the confirmation of the annual forecast in the half-year report, providing a measure of continuity during the leadership transition.
Market Sentiment and Next Catalyst
The stock has staged a notable recovery from its lows. Shares closed Friday at €48.66, up 0.4 percent on the day, bringing the year-to-date gain to 31 percent and the 12-month advance to 74 percent. The price now sits roughly 18 percent above the 200-day moving average of €41.29, underscoring the durability of the medium-term uptrend.
Just as Bayer is restructuring to manage risk across its operations, your business faces its own compliance obligations. With over 37,000 UK companies already using it, a free Health & Safety toolkit provides risk assessments and checklists covering COSHH, fire safety, and more — helping you stay compliant with current regulations. Get the free Health & Safety Toolkit
The next major test arrives shortly: on September 2, Bayer hosts its Crop Science Investor Event 2026, where management is expected to detail the future structure and strategy of the agriculture division. Given the ongoing carve-out of the US glyphosate operations, the event could prove as pivotal for the share price as the recent pharma wins — and will show whether the operational momentum can match what the market has already priced in.
